Search

To accommodate the changing needs of the developing brain, microglia must undergo substantial morphological, phenotypic, and functional reprogramming. Here, we examined whether cellular metabolism regulates microglial function during neurodevelopment. Microglial mitochondria bioenergetics correlated with and were functionally coupled to phagocytic activity in the developing brain. Transcriptional profiling of microglia with diverse metabolic profiles revealed an activation signature wherein the interleukin (IL)-33 signaling axis is associated with phagocytic activity. Genetic perturbation of IL-33 or its receptor ST2 led to microglial dystrophy, impaired synaptic function, and behavioral abnormalities. Conditional deletion of Il33 from astrocytes or Il1rl1, encoding ST2, in microglia increased susceptibility to seizures. Mechanistically, IL-33 promoted mitochondrial activity and phagocytosis in an AKT-dependent manner. Mitochondrial metabolism and AKT activity were temporally regulated in vivo. Thus, a microglia-astrocyte circuit mediated by the IL-33-ST2-AKT signaling axis supports microglial metabolic adaptation and phagocytic function during early development, with implications for neurodevelopmental and neuropsychiatric disorders., Competing Interests: Declaration of interests V.K.K. has an ownership interest and is a member of the SAB of Celsius Therapeutics and Tizona Therapeutics. V.K.K.’s interests were reviewed and managed by the Brigham and Women’s Hospital and Partners Healthcare in accordance with their conflict-of-interest policies. A.R. is a co-founder and equity holder of Celsius Therapeutics, equity holder of Immunitas, and, until August 2020, a SAB member of Thermo Fisher Scientific, Syros Pharmaceuticals, Neogene Therapeutics, and Asimov. A.R. is an employee of Genentech. O.R.-R. is an employee of Genentech. O.R.-R. is a co-inventor on patent applications filed by the Broad related to single cell genomics. All other authors declare that they have no competing interests., (Published by Elsevier Inc.)

Microglial reactivity to injury and disease is emerging as a heterogeneous, dynamic, and crucial determinant in neurological disorders. However, the plasticity and fate of disease-associated microglia (DAM) remain largely unknown. We established a lineage tracing system, leveraging the expression dynamics of secreted phosphoprotein 1（ Spp1 ） to label and track DAM-like microglia during brain injury and recovery. Fate mapping of Spp1 + microglia during stroke in juvenile mice revealed an irreversible state of DAM-like microglia that were ultimately eliminated from the injured brain. By contrast, DAM-like microglia in the neonatal stroke models exhibited high plasticity, regaining a homeostatic signature and integrating into the microglial network after recovery. Furthermore, neonatal injury had a lasting impact on microglia, rendering them intrinsically sensitized to subsequent immune challenges. Therefore, our findings highlight the plasticity and innate immune memory of neonatal microglia, shedding light on the fate of DAM-like microglia in various neuropathological conditions. [Display omitted] • Spp1 + microglia exhibit context- and age-dependent heterogeneity in neuropathologies • Fate mapping of Spp1 + microglia reveals irreversible removal of DAM in juvenile stroke • Neonatal DAM exhibits remarkable plasticity and regain homeostasis as stroke resolves • Neonatal DAM retains immune memory and increased sensitivity to future immune insults The fate of disease-associated microglia (DAM) in neuropathologies remains elusive. Lan et al. generated an Spp1 fate-mapping model to track DAM-like microglia and find that the plasticity of DAM is age dependent. Juvenile stroke leads to the elimination of DAM, whereas neonatal DAM exhibits high plasticity and reversibility after injury, along with heightened sensitivity to subsequent immune challenges. [ABSTRACT FROM AUTHOR]